MMP9 and ovarian carcinoma: These results are consistent with the abundant amount of MMP2/MMP9 reported in the ascites of ovarian cancer patients [24] and are consistent with the previous study that showed a blockade of spheroid invasion to mesothelial monolayer in the presence of GM 6001, a broad-spectrum matrix metalloproteinase inhibitor [8].